Renal Sympathetic Denervation in Patients With Hypertension and Chronic Kidney Disease: Does Improvement in Renal Function Follow Blood Pressure Control?

Journal of Clinical Hypertension

Volumn 16, Issue 11, 2014, Pages 794-800

  Kiuchi, Márcio Galindo ^a   Chen, Shaojie ^b   Andrea, Bruno Rustum ^c   Kiuchi, Tetsuaki ^d   de Queiroz Carreira, Maria Angela Magalhães ^a   Graciano, Miguel Luis ^a   Lugon, Jocemir Ronaldo ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Hospital Regional Darcy Vargas   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ALBUMIN CREATININE RATIO; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DENERVATION; MALE; PRIORITY JOURNAL; RENAL SYMPATHETIC DENERVATION; RENAL SYSTEM PARAMETERS; RESISTANT HYPERTENSION; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; BLOOD PRESSURE MEASUREMENT; HYPERTENSION; INNERVATION; KIDNEY; KIDNEY FUNCTION TEST; LONGITUDINAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; SYMPATHECTOMY;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; COMBINED MODALITY THERAPY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84929177655     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12415     Document Type: Article

References (27)

1. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41:621-624.
2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
3. Schlaich MP, Sobotka PA, Krum H, et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195-1201.
4. Mahfoud F, Lüscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-2157.
5. Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-2045.
6. Krum H, Schlaich MP, Böhm M, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-629.
7. Kiuchi MG, Maia GL, de Queiroz Carreira MA, et al. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension. Eur Heart J. 2013;34:2114-2121.
8. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
10. National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Heart, Lung, and Blood Institute (US); 2004. Report No.: 04-5230.
11. Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Nefrologia. VI Diretrizes Brasileiras de Hipertensão. Arq Bras Cardiol. 2010; 95: 1-51.
12. Merten GJ, Burgess WP, Rittase RA, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: an evidence-based protocol. Crit Path Cardiol. 2004;3:138-143.
13. ten Dam MA, Wetzels JF. Toxicity of contrast media: an update. Neth J Med. 2008;66:416-422.
14. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
15. Hausberg M, Hillebrandt U, Lang D, et al. Sympathetic overactivity in patients with chronic renal failure - the culprit of increased cardiovascular mortality? Curr Hypertens Rev. 2006;2:297-300.
16. Grassi G. Sympathetic neural activity in hypertension and related diseases. Am J Hypertens. 2010;23:1052-1060.
17. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690-697.
18. Paton JF, Raizada MK. Neurogenic hypertension. Exp Physiol. 2010;95:569-571.
19. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933-939.
20. Neumann J, Ligtenberg G, Klein II, et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int. 2004;65:1568-1576.
21. McGrath BP, Ledingham JG, Benedict CR. Catecholamines in peripheral venous plasma in patients on chronic haemodialysis. Clin Sci Mol Med. 1978;55:89-96.
22. Grassi G, Bertolli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2012;21:46-51.
23. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with endstage renal disease. Circulation. 2002;105:1354-1359.
24. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257.
25. Schlaich MP, Bart B, Hering D, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168:2214-2220.
26. Luo D, Zhang X, Lu CZ. Renal sympathetic denervation for the treatment of resistant hypertension with chronic renal failure: first-in-man experience. Chin Med J. 2013;12:1392-1393.
27. Wang L, Lu CZ, Zhang X, et al. The effect of catheter based renal sympathetic denervation on renin-angiotensin-aldosterone system in patients with resistant hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41:3-7.